Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 6, 2015, Pages 1507-1517

  Saez Llorens, Xavier ^a   Vaca, Diana Catalina Aguilera ^b   Abarca, Katia ^c   Maho, Emmanuelle ^d   Graña, Maria Gabriela ^e   Heijnen, Esther ^d   Smolenov, Igor ^d   Dull, Peter M ^f  

^a Hospital del Niño   (Panama)

^b Centro de Investigacion CAFAM   (Colombia)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d Research and Development   (Netherlands)

^e Ciudad Autonoma de Buenos Aires   (Argentina)

^f Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

Adolescents; Conjugate vaccine; Immunogenicity; Meningococcal disease; Neisseria meningitidis; Safety

Indexed keywords

MENINGOCOCCUS VACCINE; NEW DRUG; PLACEBO; VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CHILD; CONSCIOUSNESS DISORDER; DRUG FORMULATION; DRUG MISUSE; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE RASH; MALE; MENINGOCOCCOSIS; MYALGIA; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SERUM BACTERICIDAL ANTIBODY ASSAY; SKIN INDURATION; SKIN SWELLING; TRAUMATIC BRAIN INJURY; VACCINATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; PATHOLOGY; SERUM BACTERICIDAL ACTIVITY;

ADOLESCENT; BLOOD BACTERICIDAL ACTIVITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; DRUGS, INVESTIGATIONAL; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MENINGOCOCCAL VACCINES; PLACEBOS; VACCINES, COMBINED;

EID: 84944456800     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1029686     Document Type: Article

References (34)

1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88; PMID:11333996; http://dx. doi. org/10. 1056/NEJM200105033441807
2. Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, Harnden A, Mant D, Levin M. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006; 367:397-403; PMID:16458763; http://dx. doi. org/10. 1016/S0140- 6736(06)67932-4
3. Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Motal Wkly Rep 2013; 62:1-28.
4. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91; PMID:20001736; http://dx. doi. org/ 10. 1086/649209
5. World Health Organization. Meningococcal vaccines: WHO position paper, November 2011. Weekly Epidemiol Rec. 2011; 86:521-39; PMID:22128384
6. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27: B51-63; PMID:19477562; http://dx. doi. org/10. 1016/ j. vaccine. 2009. 04. 063
7. Keyserling H, Pollard AJ, DeTora LM, Gilmet GP. Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135. Expert Rev Vaccines 2006; 5:445-59; PMID:16989625; http://dx. doi. org/ 10. 1586/14760584. 5. 4. 445
8. Croxtall JD, Dhillon S. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix). Drugs 2012; 72:2407- 30; PMID:23231026; http://dx. doi. org/10. 2165/ 11209580-000000000-00000
9. Broker M, Cooper B, Detora LM, Stoddard JJ. Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease. Infect Drug Resist 2011; 4:137-47; PMID:21904459; http://dx. doi. org/ 10. 2147/IDR. S12716
10. Kelly DF, Snape MD, Clutterbuck EA, Green S, Snowden C, Diggle L, Yu LM, Borkowski A, Moxon ER, Pollard AJ. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood 2006; 108:2642-7; PMID:16675705; http://dx. doi. org/10. 1182/blood- 2006-01-009282
11. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8:851-61; http://dx. doi. org/10. 1586/ erv. 09. 48
12. Daugla D, Gami J, Gamougam K, Naibei N, Mbainadji L, Narbe M, Toralta J, Kodbesse B, Ngadoua C, ColdironM, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. Lancet 2014; 383:40-7; PMID:24035220; http://dx. doi. org/10. 1016/S0140- 6736(13)61612-8
13. Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJM, Pollard AJ, Turner DPJ et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014; 384:2123-31; PMID:25145775; http://dx. doi. org/ 10. 1016/S0140-6736(14)60842-4
14. Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299:173-84; PMID:18182599; http://dx. doi. org/10. 1001/jama. 2007. 29-c
15. Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM; V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009; 49:e1-10; PMID:19476428; http:// dx. doi. org/10. 1086/599117
16. Stamboulian D, Lopardo G, Lopez P, Cortes-Barbosa C, Valencia A, Bedell L, Karsten A, Dull PM. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, Men- ACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis 2010; 14: e868-75; PMID:20655261; http://dx. doi. org/10. 1016/ j. ijid. 2010. 03. 017
17. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138:4402-7; PMID:3108388
18. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511-20; PMID:20410516; http://dx. doi. org/10. 1056/NEJMra0906357
19. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287:1816-20; PMID:10710308; http://dx. doi. org/ 10. 1126/science. 287. 5459. 1816
20. Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Scie U S A 2006; 103: 10834-39; http://dx. doi. org/ 10. 1073/pnas. 0603940103
21. Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Disease J 2010; 29:e71-9; http://dx. doi. org/10. 1097/ INF. 0b013e3181b0602e
22. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010; 51:1127-37; PMID:20954968; http://dx. doi. org/10. 1086/656741
23. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307:573-82; PMID:22318278; http://dx. doi. org/ 10. 1001/jama. 2012. 85
24. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011; 18:483-6; PMID:21177912; http://dx. doi. org/ 10. 1128/CVI. 00304-10
25. Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, Toneatto D, Grana G, Wang H, Clemens R, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379:617-24; PMID:22260988; http://dx. doi. org/10. 1016/S0140- 6736(11)61713-3
26. Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013; 381:825-35; PMID:23324563; http://dx. doi. org/10. 1016/S0140-6736(12)61961-8
27. Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 2010;10:175; PMID:20565757; http://dx. doi. org/ 10. 1186/1471-2334-10-175
28. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W- 135, and X strains from Africa. J Infect Dis 2009; 199 (9):1360-8; PMID:19302008; http://dx. doi. org/ 10. 1086/597806
29. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 2011; 5: e1302; PMID:21909444; http://dx. doi. org/10. 1371/ journal. pntd. 0001302
30. Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, Dull P, Pizza M, Taha MK. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine 2013; 31:1113-6; PMID:23261039; http:// dx. doi. org/10. 1016/j. vaccine. 2012. 12. 022
31. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010; 107:19490-95; http://dx. doi. org/10. 1073/ pnas. 1013758107
32. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009; 27: B3-12; PMID:19481313; http://dx. doi. org/10. 1016/j. vaccine. 2009. 04. 071
33. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27S: B112-16; http://dx. doi. org/10. 1016/j. vaccine. 2009. 04. 065
34. Mak PA, Santos GF, Masterman K-A, Janes J, Wacknov B, Vienken K, Giuliani M, Herman AE, Cooke M, Mbow ML, et al. Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis. Clin Vaccine Immunol 2011; 18:1252-60; PMID:21715580; http://dx. doi. org/10. 1128/CVI. 05028-11